These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553 [TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418 [TBL] [Abstract][Full Text] [Related]
11. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422 [TBL] [Abstract][Full Text] [Related]
12. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients]. Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830 [TBL] [Abstract][Full Text] [Related]
15. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206 [TBL] [Abstract][Full Text] [Related]
16. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376 [TBL] [Abstract][Full Text] [Related]
17. Quality of life on imatinib. Hahn EA; Glendenning GA Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373 [TBL] [Abstract][Full Text] [Related]
18. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Qin Y; Jiang B; Jiang Q; Jiang H; Li J; Zhang Y; Zhu H; Li L; Chen S; Liu Y; Huang X Ann Hematol; 2009 Jan; 88(1):37-41. PubMed ID: 18651143 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681 [TBL] [Abstract][Full Text] [Related]
20. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]